SLC5A2 and chronic kidney disease: This breakthrough has led KDIGO to recommend treating CKD patients with type 2 diabetes and an eGFR at least 20 ml/min/1.73 m2 with an SGLT2 inhibitor, irrespective of the level of albuminuria.